Equities

Observe Medical ASA

Observe Medical ASA

Actions
Health CareMedical Equipment and Services
  • Price (NOK)0.364
  • Today's Change-0.002 / -0.55%
  • Shares traded154.13k
  • 1 Year change-22.80%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Observe Medical ASA is a Norway-based medtech company that develops, markets and sells medtech products for the global market. The Company has a broad distribution portfolio of medtech devices and disposables, mainly within Urine measurement, Anesthesiology/ICUs and wound care. The Company is recognized for development and distribution of the Sippi automated digital urine system. Sippi is consist of several products like urine temperature catheters fixating devices to use in combination with urine catheters. Another product Biim is s approved for ultrasound imaging of the human body and is specifically used to guide needle and catheter insertions for dialysis and vascular access procedures. Observe Medical ASA is the parent company of its wholly owned subsidiaries, Observe Medical International AS, Observe Medical AB, Observe Medical ApS, Observe Medical Nordic AB and Biim Ultrasound AS.

  • Revenue in NOK (TTM)--
  • Net income in NOK--
  • Incorporated2019
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ScandiDos AB61.53m-9.70m75.48m26.00--2.15--1.23-0.2068-0.20681.260.7660.81841.316.881,978,871.00-12.90-12.60-23.54-21.7650.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
Ortivus AB78.20m-17.85m79.41m32.00--32.47--1.02-0.4016-0.40161.760.05380.9036--23.271,949,050.00-20.62-2.41-41.25-4.6336.3842.46-22.82-1.770.4251-7.580.9447---19.5510.00-409.66--67.43--
SciBase Holding AB (publ)26.95m-64.40m85.88m27.00--2.26--3.19-0.4237-0.42370.16650.17260.38510.72223.30995,185.20-92.01-68.63-122.20-87.7772.2961.28-238.95-300.202.44-14.840.00--29.9327.50-28.75--5.15--
Kontigo Care AB30.20m993.01k92.58m10.0098.362.1720.153.070.02930.02931.041.330.6232--8.46--2.05-0.42142.80-0.619566.7766.313.29-0.5205--12.010.0922--1.8016.95-92.68--44.94--
Dignitana AB86.76m-25.35m99.37m29.00--10.12--1.15-0.3268-0.32681.130.12151.742.7615.193,203,482.00-50.91-42.21-122.38-68.9169.5666.09-29.22-57.290.5202-9.970.609--17.9020.5922.52---15.31--
Episurf Medical AB12.84m-79.94m99.65m26.00--0.9795--7.76-0.2072-0.20720.03010.15580.1059--5.57457,142.80-66.09-47.46-75.45-52.01-----624.22-1,019.296.17--0.0296--53.6219.78-22.64---0.4158--
Immunovia AB (publ)887.69k-116.47m100.26m10.00--2.72--112.95-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Observe Medical ASA-100.00bn-100.00bn101.82m5.00--0.6495----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Iconovo AB2.93m-40.33m107.30m28.00--0.7183--36.68-2.74-2.740.1967.020.0215--1.14100,561.70-29.61-25.43-33.16-28.24635.97134.57-1,378.66-215.16---1,179.070.0668---58.65-9.884.71--34.70--
Vo2 Cap Holding AB (publ)349.09m-55.31m108.12m94.00--0.5989--0.3097-0.9759-0.97596.463.160.7992--8.213,378,952.00-12.66-0.2564-17.29-0.383935.7823.36-15.84-0.2409---6.950.1429---26.0985.65-57.92---17.96--
Luxbright AB4.22m-22.30m112.46m10.00--3.77--26.68-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Redsense Medical AB (publ)23.84m-3.99m113.81m5.00--3.53--4.77-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
BibbInstruments AB0.00-12.25m118.93m4.00--3.69-----0.4477-0.44770.001.100.00-------34.78-39.57-36.66-42.71--59.36---8,032.404.41--0.00------2.72---1.94--
Q linea AB2.27m-219.00m128.33m97.00--4.99--56.46-1.87-1.870.01940.2190.01070.12243.0117,842.52-103.05-59.66-149.74-66.14-124.10-378.58-9,635.17-4,046.970.4141--0.7825---65.2833.0214.64--41.94--
Arcoma AB171.85m13.02m136.89m32.0010.512.316.670.79650.98440.984412.994.481.873.487.875,526,807.0014.181.1224.212.0138.2937.667.580.75681.2425.820.000.0030.366.4134.81--22.75--
Glycorex Transplantation AB (publ)31.12m-27.91m138.06m15.00--3.76--4.44-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
Data as of Nov 21 2024. Currency figures normalised to Observe Medical ASA's reporting currency: Norwegian Krone NOK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.